## Brian J Davis

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6361606/publications.pdf

Version: 2024-02-01

87886 74160 6,052 126 38 75 citations h-index g-index papers 126 126 126 6706 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	4.9	544
2	American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy, 2012, 11, 6-19.	0.5	399
3	Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline. Journal of Urology, 2013, 190, 441-449.	0.4	368
4	Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. International Journal of Radiation Oncology Biology Physics, 2004, 59, 419-425.	0.8	325
5	External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M. D. Anderson Cancer Center. International Journal of Radiation Oncology Biology Physics, 1997, 37, 753-759.	0.8	183
6	Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 3864-3871.	1.6	177
7	Adjuvant and Salvage Radiation Therapy After Prostatectomy: American Society for Radiation Oncology/American Urological Association Guidelines. International Journal of Radiation Oncology Biology Physics, 2013, 86, 822-828.	0.8	161
8	A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy. PLoS ONE, 2008, 3, e2318.	2.5	160
9	Planning Target Margin Calculations for Prostate Radiotherapy Based on Intrafraction and Interfraction Motion Using Four Localization Methods. International Journal of Radiation Oncology Biology Physics, 2008, 70, 289-295.	0.8	148
10	URINARY FISTULAS FOLLOWING EXTERNAL RADIATION OR PERMANENT BRACHYTHERAPY FOR THE TREATMENT OF PROSTATE CANCER. Journal of Urology, 2005, 173, 1953-1957.	0.4	145
11	Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease. Practical Radiation Oncology, 2018, 8, 28-39.	2.1	140
12	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). European Urology, 2021, 80, 280-292.	1.9	140
13	The radial distance of extraprostatic extension of prostate carcinoma., 1999, 85, 2630-2637.		134
14	Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7–10 Prostate Cancer Treated With Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 341-346.	0.8	126
15	LC-MS/MS Quantification of Zn-α2 Glycoprotein: A Potential Serum Biomarker for Prostate Cancer. Clinical Chemistry, 2007, 53, 673-678.	3.2	123
16	Metastatic prostate carcinoma to bone. Cancer, 2002, 95, 1028-1036.	4.1	122
17	Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Frontiers in Oncology, 2012, 2, 215.	2.8	107
18	HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncology, The, 2016, 17, 1435-1444.	10.7	107

#	Article	IF	CITATIONS
19	The evolution of brachytherapy for prostate cancer. Nature Reviews Urology, 2017, 14, 415-439.	3.8	106
20	Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Research, 2015, 75, 4688-4696.	0.9	105
21	Customized Dose Prescription for Permanent Prostate Brachytherapy: Insights From a Multicenter Analysis of Dosimetry Outcomes. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1472-1477.	0.8	92
22	Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1131-1140.	0.8	85
23	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 174-185.	0.8	77
24	Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Irradiation. Journal of Urology, 2006, 176, 2020-2024.	0.4	73
25	Prostate brachytherapy seed localization by analysis of multiple projections: Identifying and addressing the seed overlap problem. Medical Physics, 2004, 31, 1277-1287.	3.0	62
26	A Preclinical Large Animal Model of Adenovirus-Mediated Expression of the Sodium–lodide Symporter for Radioiodide Imaging and Therapy of Locally Recurrent Prostate Cancer. Molecular Therapy, 2005, 12, 835-841.	8.2	62
27	Postoperative Nomogram Predicting the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic Variable. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1061-1065.	0.8	59
28	Natural History of Clinical Recurrence Patterns of Lymph Node–Positive Prostate Cancer After Radical Prostatectomy. European Urology, 2016, 69, 135-142.	1.9	58
29	PROSTATE BRACHYTHERAPY SEED MIGRATION TO THE RIGHT VENTRICLE FOUND AT AUTOPSY FOLLOWING ACUTE CARDIAC DYSRHYTHMIA. Journal of Urology, 2000, 164, 1661-1661.	0.4	57
30	Magnetic Resonance Imaging-guided Cryoablation of Recurrent Prostate Cancer After Radical Prostatectomy: Initial Single Institution Experience. Urology, 2013, 82, 870-875.	1.0	56
31	Prostate Brachytherapy Seed Migration To A Coronary Artery Found During Angiography. Journal of Urology, 2002, 168, 1103-1103.	0.4	51
32	Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. European Urology, 2017, 71, 340-348.	1.9	51
33	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	7.1	49
34	Telemedicine in radiotherapy treatment planning: requirements and applications. Radiotherapy and Oncology, 2000, 54, 255-259.	0.6	48
35	Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy, 2007, 6, 2-8.	0.5	47
36	Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology, 2000, 56, 726-729.	1.0	45

#	Article	IF	Citations
37	Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with <sup>11</sup> C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2017, 197, 129-134.	0.4	45
38	Prostate Cryotherapy Monitoring Using Vibroacoustography: Preliminary Results of an <i>Ex Vivo</i> Study and Technical Feasibility. IEEE Transactions on Biomedical Engineering, 2008, 55, 2584-2592.	4.2	44
39	Electronic and film portal images: a comparison of landmark visibility and review accuracy. International Journal of Radiation Oncology Biology Physics, 2002, 54, 584-591.	0.8	42
40	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2018, 129, 377-386.	0.6	39
41	A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. Brachytherapy, 2012, 11, 299-305.	0.5	35
42	Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2017, 97, 526-535.	0.8	35
43	Progress in Gene Therapy for Prostate Cancer. Frontiers in Oncology, 2012, 2, 172.	2.8	34
44	The radial distance of extraprostatic extension of prostate carcinoma. Cancer, 1999, 85, 2630-2637.	4.1	34
45	3D visualization, analysis, and treatment of the prostate using trans-urethral ultrasound. Computerized Medical Imaging and Graphics, 2003, 27, 339-349.	5.8	30
46	Low dose rate prostate brachytherapy. Translational Andrology and Urology, 2018, 7, 341-356.	1.4	30
47	ACR Appropriateness Criteria $\hat{A}^{\otimes}$ external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Advances in Radiation Oncology, 2017, 2, 62-84.	1.2	30
48	Seed localization and TRUS-fluoroscopy fusion for intraoperative prostate brachytherapy dosimetry. Computer Aided Surgery, 2007, 12, 25-34.	1.8	29
49	Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry. Physics in Medicine and Biology, 2007, 52, 3105-3119.	3.0	28
50	Treatment of Prostate Cancer Local Recurrence After Radical Retropubic Prostatectomy with 17-Gauge Interstitial Transperineal Cryoablation: Initial Experience. Urology, 2007, 70, 80-85.	1.0	28
51	Examination of dosimetry accuracy as a function of seed detection rate in permanent prostate brachytherapy. Medical Physics, 2005, 32, 3049-3056.	3.0	27
52	Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. Practical Radiation Oncology, 2016, 6, e117-e126.	2.1	26
53	ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy, 2017, 16, 266-276.	0.5	26
54	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy, 2021, 20, 1114-1129.	0.5	26

#	Article	IF	CITATIONS
55	ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2014, 13, 27-31.	0.5	24
56	Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. International Journal of Radiation Oncology Biology Physics, 2019, 103, 229-240.	0.8	24
57	Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 767-776.	0.8	23
58	ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Advances in Radiation Oncology, 2017, 2, 437-454.	1.2	21
59	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 6376-6383.	7.0	21
60	Measurement of the ultrasound backscatter signal from three seed types as a function of incidence angle: Application to permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1174-1182.	0.8	20
61	Long-Term Outcomes After Maximal Surgical Resection and Intraoperative Electron Radiotherapy for Locoregionally Recurrent or Locoregionally Advanced Primary Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1938-1943.	0.8	20
62	Long-term outcomes of radiotherapy for stage II testicular seminoma–the Mayo Clinic experience. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1832-1838.	1.6	20
63	ACR Appropriateness Criteria ® Post-treatmentÂFollow-up Prostate Cancer. Journal of the American College of Radiology, 2018, 15, S132-S149.	1.8	20
64	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2019, 140, 68-75.	0.6	20
65	Prostate Volume Before and After Permanent Prostate Brachytherapy in Patients Receiving Neoadjuvant Androgen Suppression. Cancer Journal (Sudbury, Mass), 2004, 10, 343-348.	2.0	19
66	Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. Brachytherapy, 2019, 18, 1-7.	0.5	19
67	A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1082-1089.	0.8	19
68	Prediction of Radial Distance of Extraprostatic Extension FromÂPretherapy Factors. International Journal of Radiation Oncology Biology Physics, 2007, 69, 411-418.	0.8	18
69	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. JAMA Oncology, 2022, 8, e216871.	7.1	18
70	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open, 2021, 4, e2138550.	5.9	18
71	Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. Current Opinion in Urology, 2003, 13, 117-122.	1.8	17
72	Brachytherapy in the Management of Prostate Cancer. Surgical Oncology Clinics of North America, 2017, 26, 491-513.	1.5	17

#	Article	IF	CITATIONS
73	Detection of recurrent prostate cancer after primary radiation therapy: An evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil. Practical Radiation Oncology, 2017, 7, 42-49.	2.1	17
74	Application of vibro-acoustography in prostate tissue imaging. Medical Physics, 2013, 40, 022902.	3.0	14
75	Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy. Brachytherapy, 2003, 2, 98-102.	0.5	13
76	ACR Appropriateness Criteria® Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 278-288.	1.3	13
77	Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using <sup>11</sup> C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging. Journal of Urology, 2018, 199, 726-733.	0.4	13
78	The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer, 2002, 95, 513-519.	4.1	12
79	Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminomaâ€"The Mayo Clinic experience. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 24.e1-24.e6.	1.6	12
80	Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds. Brachytherapy, 2019, 18, 306-312.	0.5	12
81	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Network Open, 2021, 4, e2115312.	5.9	12
82	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. European Urology, 2021, 80, 142-146.	1.9	12
83	Estimated limits of IMRT dose escalation using varied planning target volume margins. Physics in Medicine and Biology, 2008, 53, 3777-3788.	3.0	11
84	The American Board of Radiology Initial Certification in Radiation Oncology: Moving Forward Through Collaboration. International Journal of Radiation Oncology Biology Physics, 2019, 104, 21-23.	0.8	11
85	Fluoroscopy to ultrasound image registration using implanted seeds as fiducials during permanent prostate brachytherapy. , 2004, , .		10
86	Permanent prostate brachytherapy: Pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy. Urology, 2006, 68, 810-814.	1.0	10
87	Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer and Prostatic Diseases, 2021, 24, 514-523.	3.9	10
88	Prostate brachytherapy seed reconstruction using an adaptive grouping technique. Medical Physics, 2007, 34, 2975-2984.	3.0	9
89	Late gastrointestinal morbidity in patients with stage l–ll testicular seminoma treated with radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 496-500.	1.6	9
90	Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. Advances in Radiation Oncology, 2019, 4, 314-322.	1.2	9

#	Article	IF	CITATIONS
91	$^{\circ}$ sup>11C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen $^{\circ}$ and $^{\circ}$ 358.	0.9	8
92	Prostate brachytherapy seed migration to a coronary artery found during angiography. Journal of Urology, 2002, 168, 1103.	0.4	8
93	Multimodality Therapy Including Surgical Resection and Intraoperative Electron Radiotherapy for Recurrent or Advanced Primary Carcinoma of the Urinary Bladder or Ureter. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 596-600.	1.3	7
94	Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence. Clinical Genitourinary Cancer, 2019, 17, e536-e540.	1.9	6
95	Comparing bowel and urinary domains of patientâ€reported quality of life at the end of and 3 months post radiotherapy between intensityâ€modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. Cancer Medicine, 2020, 9, 7925-7934.	2.8	6
96	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 953-963.	0.8	6
97	The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer. Radiotherapy and Oncology, 2021, 161, 9-15.	0.6	6
98	Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. BJU International, 2006, 98, 773-776.	2.5	5
99	Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus '. Radiation Oncology, 2014, 9, 171.	2.7	5
100	Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. Journal of Contemporary Brachytherapy, 2016, 5, 371-378.	0.9	5
101	178 Supplemental implantation for suboptimal permanent prostate brachytherapy: A prostate phantom study. Radiotherapy and Oncology, 2000, 55, 91-92.	0.6	4
102	Brachytherapy Seed Localization from Fluoroscopic Images Using a Statistical Classifier. Lecture Notes in Computer Science, 2003, , 945-946.	1.3	4
103	Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the prostate using an automated seed sorting algorithm. Brachytherapy, 2004, 3, 106-112.	0.5	4
104	The Relationship of the Intensity of Posttreatment Prostate-Specific Antigen Surveillance and Prostate Cancer Outcomes: Results From a Population-Based Cohort. Mayo Clinic Proceedings, 2012, 87, 540-547.	3.0	4
105	Feasibility of vibroâ€acoustography with a quasiâ€2D ultrasound array transducer for detection and localizing of permanent prostate brachytherapy seeds: A pilot ⟨i⟩ex vivo⟨/i⟩ study. Medical Physics, 2014, 41, 092902.	3.0	4
106	TRUS-fluoroscopy fusion for intraoperative prostate brachytherapy dosimetry. Studies in Health Technology and Informatics, 2006, 119, 532-7.	0.3	4
107	<title>Transurethral ultrasound of the prostrate for applications in prostrate brachytherapy: analysis of phantom and in-vivo data</title> ., 2001, , .		3
108	Vibro-acoustography with 1.75D ultrasound array transducer for detection and localization of permanent prostate brachytherapy seeds: ex vivostudy. , 2013, , .		3

#	Article	IF	CITATIONS
109	Shape analysis of the prostate: Establishing imaging specifications for the design of a transurethral imaging device for prostate brachytherapy guidance. Brachytherapy, 2014, 13, 465-470.	0.5	2
110	Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. Advances in Radiation Oncology, 2019, 4, 79-89.	1.2	2
111	Oligometastatic prostatic cancer recurrence: role of salvage lymph node dissection (sLND) and radiation therapy-stereotactic body radiation therapy (RT-SBRT). Current Opinion in Urology, 2021, 31, 199-205.	1.8	2
112	Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy. Practical Radiation Oncology, 2021, 11, e468-e476.	2.1	2
113	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. Bladder, 2018, 5, e34.	0.2	2
114	Morbidity After Brachytherapy for Prostate Adenocarcinoma. Mayo Clinic Proceedings, 2004, 79, 946-947.	3.0	1
115	Treatment of localised prostate cancer with radiation therapy: evidence versus opinion. Clinical and Translational Oncology, 2010, 12, 315-317.	2.4	1
116	Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center. Practical Radiation Oncology, 2020, 10, e378-e387.	2.1	1
117	A method for size estimation for small objects and its application in brachytherapy seed identification. , 2004, , .		0
118	LETTER TO THE EDITOR. Cancer Journal (Sudbury, Mass ), 2005, 11, 432.	2.0	0
119	Seed based registration for intraoperative brachytherapy dosimetry: a comparison of methods. , 2006, , .		0
120	In Reply to Drs. Oton and Oton. International Journal of Radiation Oncology Biology Physics, 2008, 71, 962-963.	0.8	0
121	Response to Drs Rogers, Hayes, and Demanes. Brachytherapy, 2014, 13, 523-525.	0.5	O
122	Reply from Authors re: Alberto Bossi, Nicolas Mottet, Pierre Blanchard. Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? Eur Urol 2017;71:349–50. European Urology, 2017, 71, 351-352.	1.9	0
123	Sternum First, Perhaps Pelvis Later. International Journal of Radiation Oncology Biology Physics, 2017, 98, 496.	0.8	O
124	In response to Dover et al Practical Radiation Oncology, 2021, , .	2.1	0
125	PSA screening in men newly diagnosed with colorectal cancer: each according to his group's means?. Oncology, 2013, 27, 1038, 1040.	0.5	0
126	The ABR 2021 Radiation Oncology Remote Examinations: Development, Administration, and Implications for the Future. Journal of the American College of Radiology, 2022, , .	1.8	0